Galera to Present at Two Upcoming Investor Conferences in November
November 15 2021 - 7:00AM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, today announced that
Mel Sorensen, M.D., President and Chief Executive Officer, will
present at two upcoming investor conferences in November.
Presentation Details: |
|
|
Event: |
Jefferies London Healthcare
Conference |
Date: |
November 18, 2021 |
Time: |
On-demand beginning at 8:00
a.m. GMT (3:00 a.m. ET) |
|
|
Event: |
Piper Sandler Annual
Healthcare Conference |
Date: |
November 22, 2021 |
Time: |
On-demand beginning at 10 a.m.
ET |
Webcasts from the two presentations will be accessible from the
Investors page of Galera’s website, investors.galeratx.com.
Following the event, archived webcasts will be available on the
Galera website for 30 days.
About Galera TherapeuticsGalera Therapeutics,
Inc. is a clinical-stage biopharmaceutical company focused on
developing and commercializing a pipeline of novel, proprietary
therapeutic candidates that have the potential to transform
radiotherapy in cancer. Galera’s technology consists of selective
small molecule dismutase mimetics that are in late-stage
development in patients with cancer. Avasopasem manganese (GC4419,
also referred to as avasopasem) is in development for
radiotherapy-induced toxicities, including SOM in patients with
head and neck cancer and esophagitis in patients with lung cancer.
Avasopasem has been granted FDA Fast Track and Breakthrough Therapy
designations for the reduction of SOM induced by radiotherapy, with
or without systemic therapy. Galera’s second dismutase mimetic
product candidate, rucosopasem manganese (GC4711, also referred to
as rucosopasem), is in clinical-stage development to augment the
anti-cancer efficacy of stereotactic body radiation therapy in
patients with non-small cell lung cancer and locally advanced
pancreatic cancer. Galera is headquartered in Malvern, PA. For more
information, please visit www.galeratx.com.
Investor Contacts:Christopher DegnanGalera
Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
William WindhamSolebury
Trout646-378-2946wwindham@soleburytrout.com
Media Contact:Zara LockshinSolebury
Trout646-378-2960zlockshin@soleburytrout.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024